Press Release NKI/WUR/Surfix

Amsterdam and Wageningen, Netherlands, July 9th 2025: Today, Surfix alongside the Netherlands Cancer Institute (NKI) and Wageningen University & Research (WUR), have launched a collaborative initiative to improve outcomes for cancer patients receiving immunotherapy treatment, who are therefore at risk of developing adrenal insufficiency. By combining cutting-edge photonic technology with world-class medical and academic expertise, the partners aim to detect cortisol deficiencies early—at the point of care—helping to prevent irreversible damage. The new partnership is established in the Yolofitis project, supported by a PPP grant from the TKI-program Life Sciences & Health of Health~Holland.

The full text of the Press Release can be found here.